Nestlé Health Science Collaborate with Aimmune on Food Allergy Project

636141924688079833allergens.jpg

08 Nov 2016 --- Nestlé Health Science has announced that it will make an equity investment of $145 million in US-based Aimmune Therapeutics, to accelerate the development of technology designed to desensitize people with food allergies, protecting them from the consequences of accidental exposure. 

Up to 250 million people globally are estimated to suffer from food allergies, between 5-8% of who children and 1-2% of adults.

Amongst the top eight food allergies, peanut allergy, which is generally a lifelong condition, is estimated to impact 6 million people in the US and in Europe or between 0.6 and 1.3% of the population in the US.

Aimmune’s Characterized Oral Desensitization ImmunoTherapy approach to treating life-threatening food allergies is based on extensive independent scientific research.

It demonstrates that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular, food, through the oral administration of gradually increasing amounts of the allergens.

It aims to provide a transformative treatment option that goes beyond the current standard of care of avoiding food allergens and carrying epinephrine for administration in case of accidental exposure.

Greg Behar, CEO of Nestlé Health Science, who will take a seat on the Aimmune Board, stated: “Food allergies have a huge personal impact and are a health economic burden.”

“We are investing and innovating to change the approach to food allergy management with integrated approaches from diagnostics to nutrition solutions and now biologics, where Aimmune’s proprietary approach has transformational potential in lives of patients and families.”

Aimmune’s lead Characterized Oral Desensitization ImmunoTherapy product candidate, AR101 for peanut allergy, is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts designed to desensitize patients with peanut allergy.

The ongoing Phase III trial, conducted by Aimmune, is expected to deliver results in 4Q2017, which – if positive – may support the filing of marketing authorization in the US and Europe.

Stephen Dilly, CEO of Aimmune, said, “Nestlé Health Science is an ideal partner that brings a shared vision, global scale and complementary capabilities to this collaboration, making the whole more than the sum of the parts.”

“We are excited to have Nestlé Health Science alongside as we pursue our development plans and seek to realize the full promise of our CODIT approach by addressing the important questions in food allergy around optimizing treatments, achieving sustained unresponsiveness, and exploring the science around tolerance.”

Having already established a portfolio of nutritional solutions for pediatric food allergy and intolerances, the investment extends Nestlé Health Science’s interests in the food allergy arena.  

The strategic investment launches a two-year strategic collaboration between the two companies, the terms of which enable the parties to engage on Aimmune’s current and future oral immunotherapy development programs through a newly established pipeline forum.

Nestlé Health Science will provide ongoing scientific, regulatory and commercial expertise and advice to Aimmune through the pipeline forum, and in addition, has a three-month exclusive right of first negotiation for any development program in the event Aimmune considers licensing or partnering such a program.

Related Articles

Nutrition & Health News

Plant power: Optimum Nutrition launches brand's first plant-based protein

23 Feb 2018 --- Performance nutrition supplier Optimum Nutrition ("ON") is expanding its Gold Standard protein line with the brand's first plant-based protein powder. Fitting nicely within the trend toward plant-based offerings to suit athletes of all levels, ON Gold Standard 100% Plant has a multisource blend of premium, plant-based protein that delivers a complete profile of essential amino acids, outstanding taste and texture, without any artificial flavors, colors or sweeteners.

Nutrition & Health News

Collagen peptides: Innovation platforms far from exhausted, says Rousselot exec

22 Feb 2018 --- Boosted by a growing body of scientific research, collagen peptides have risen in popularity over the past years. In fact, Innova Market Insights figures show that there was a +34 percent compound annual growth rate (CAGR) in new product launches for collagen peptides from 2010 to 2016. However, there is still ample room for further growth and research, according to Lisette van Lith, Global Director of Rousselot's Peptan, who spoke with NutritionInsight about her new role and regional inspiration for the usage of collagen peptides. 

Nutrition & Health News

Low-fat and low-carb diets equally effective, Stanford study finds

21 Feb 2018 --- After years of debate, a new study at the Stanford University School of Medicine has found that neither a low-fat nor a low-carb diet is superior: Cutting either carbs or fats leads to a reduction of excess weight in about the same proportion, according to the study. The study also looked into whether insulin levels or a specific genotype pattern could predict an individual's success on either diet. The answer, in both cases, was no.

Nutrition & Health News

Low-carb diet found to help battle fatty liver disease

20 Feb 2018 --- A carbohydrate-restricted diet can lead to “rapid and dramatic” reductions of liver fat and other cardiometabolic risk factors, along with marked decreases in the synthesis of hepatic fat, reveals a study published last week in Cell Metabolism. The study results could lead to improved treatments for non-alcoholic fatty liver disease (NAFLD). 

Nutrition & Health News

A gold medal for recovery? FrieslandCampina DMV develops innovative casein isolate 

14 Feb 2018 --- FrieslandCampina DMV has introduced their latest innovation in dairy protein ingredients. Micelate Prestige has been launched this week in Europe and is a key addition to the company’s growing portfolio of Performance Nutrition solutions. 

More Articles
URL : http://www.nutritioninsight.com:80/news/nestl%C3%A9-health-science-collaborate-with-aimmune-on-food-allergy-project.html